Trial site
Oculomedica Sp. z o.o.
Bydgoszcz, 85-157, PolandEU-13 widening countryNot linked to an institution yet
- 11running trials
- 4closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 24 trials
- Phase 2/34 trials
- Status
- Active, not recruiting4 trials
- Completed4 trials
- Recruiting4 trials
- Not yet recruiting3 trials
- Lead sponsor
- Eyebiotech Limited2 trials
- Apellis Pharmaceuticals, Inc.1 trial
- Boehringer Ingelheim1 trial
- EyeBiotech Ltd.1 trial
- Eyepoint Inc.1 trial
- and 9 more
Running trials
Not yet recruiting
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
2026-526648-11-00· Phase 2/3· Shenzhen Oculgen Biomedical Technology Co. Ltd.· Source
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365· Phase 2· Sitala Bio LTD· Source
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00· Phase 2/3· Eyebiotech Limited· Source
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025-523937-25-00· Phase 3· Eyepoint Inc.· Source
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source
Active, not recruiting
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error